DRTG(SH:600329) 智通财经网·2025-11-25 07:54Core Viewpoint - Darentang (600329.SH) has received approval from the National Medical Products Administration for the registration of Loxoprofen Sodium Gel Patch, which is intended for the treatment of inflammation and pain associated with osteoarthritis, muscle pain, and post-injury swelling and pain [1] Group 1: Product Development - The company aims to establish a modern traditional Chinese medicine patch technology platform that integrates "R&D - production - quality control" capabilities [1] - The approval of Loxoprofen Sodium Gel Patch signifies that the product meets the relevant requirements for drug registration and will not have a significant impact on the company's recent performance [1] Group 2: Future Strategy - The company plans to continue building a product matrix that covers "chemical drugs - traditional Chinese medicine - health patches," providing more medication options and improving the medication experience for patients [1]